STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients - Khatri - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Figure 2 | Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials | SpringerLink
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
Data from the Otezla ESTEEM Clinical Trial | Otezla® (apremilast) Healthcare Professional Site
Pediatric Psoriasis Before & After Results | Taltz® (ixekizumab)
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
Proportions of patients who achieved (a) PASI-75 and (b) PASI-50 and... | Download Scientific Diagram
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture
Figure 2 | Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis | SpringerLink
Deucravacitinib superior to placebo, apremilast in phase 3 plaque psoriasis trials
Plaque Psoriasis Efficacy | Enbrel® (etanercept)
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect
Plaque Psoriasis Skin Clearance | COSENTYX® (secukinumab)
Evolution of psoriasis endpoint use - IQVIA
PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram
Time course of PASI 75, PASI 90, sPGA 0/1, and DLQI overall score of... | Download Scientific Diagram
Solved Health State transition PASI 75 maintain PASI 75 PASI | Chegg.com
PASI-75 Response with Otezla in the Treatment of Moderate to Severe Plaque Psoriasis — Efficacy | Otezla® (apremilast) Healthcare Professional Site
Treatment Efficacy | Dermatology | Taltz (ixekizumab)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis | NEJM
Moderate to severe plaque psoriasis | CIMZIA® (certolizumab pegol)
PASI 75 response over time in FIXTURE study. 3 Green and orange arrows... | Download Scientific Diagram
